Ximelagatran as a new oral anticoagulant for thrombosis.
Dahl
Ola E
OE
Thrombosis Research Institute, London, United Kingdom.
Michiels
Jan Jacques
JJ
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000139:chemically induced; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000517:prevention & control / Q000628:therapy*; D014812:Vitamin K / Q000037:antagonists & inhibitors; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D014812:Vitamin K; C426686:ximelagatran; D014859:Warfarin; D013917:Thrombin